Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBG-1600M
- Development stage
- Phase 1
- Lead developer
- Suzhou Longbotai Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LBG-1600M is a topical small molecule Janus kinase 1 (JAK1) inhibitor developed by Suzhou Longbotai Pharmaceutical for the treatment of atopic dermatitis. By selectively inhibiting the JAK1 enzyme, the drug modulates the signaling pathways of several pro-inflammatory cytokines, such as IL-4, IL-13, and IL-31, which are central to the pathogenesis of atopic dermatitis. This mechanism helps to reduce skin inflammation and alleviate pruritus. LBG-1600M is formulated as an ointment for topical application, designed to provide localized therapeutic effects while minimizing the systemic exposure and associated side effects often seen with oral JAK inhibitors.
02
Targets
Beyond the preview
Go deeper on LBG-1600M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBG-1600M.